May 17, 2013
Research explores data on treatments for psychiatric disorders; health economics and outcomes research also
Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association (APA) 166th Annual Meeting in
. The data being presented represent Shire's ongoing commitment to the clinical research of Vyvanse
(lisdexamfetamine dimesylate) Capsules, (CII) and INTUNIV® (guanfacine) Extended-Release Tablets, its approved prescription medicines for Attention-Deficit/Hyperactivity Disorder (ADHD). Data being presented include post-hoc analyses from several of its phase 2 clinical studies investigating potential new psychiatric uses of Vyvanse for the adjunctive treatment for Major Depressive Disorder (MDD) and for the treatment of Binge Eating Disorder (BED). Shire also will present health economic data on INTUNIV and outcomes research in ADHD. Vyvanse and INTUNIV should only be used to treat ADHD.
"Shire is committed to research in the field of neuroscience and developing treatment options for conditions that have significant unmet patient need, such as MDD and BED," said Arnaud Partiot, MD, PhD, Shire senior vice president, Research and Development.
Vyvanse is a once-daily prescription medication for patients ages 6 and above with Attention-Deficit/Hyperactivity disorder (ADHD) and may be used as part of a total treatment program that may include counseling or other therapies.
Vyvanse is a Schedule II controlled substance. CNS stimulants (amphetamines and methylphenidate-cont
aining products) have a high potential for abuse and dependence. Assess the risk of abuse prior
prescribing and moni
r for signs of abuse and dependence.
INTUNIV is indicated for the treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications in children and adolescents ages 6 to 17. The effectiveness of INTUNIV for more than 8 weeks has not been systematically evaluated. The physician electing to use INTUNIV for extended periods should periodically reevaluate its long-term usefulness for the individual patient.